Chongqing Lummy Pharmaceutical (SZSE:300006) Accounts Payable & Accrued Expense : ¥471.5 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Chongqing Lummy Pharmaceutical Accounts Payable & Accrued Expense?

Chongqing Lummy Pharmaceutical's quarterly accounts payable & accrued expense declined from Sep. 2023 (¥420.1 Mil) to Dec. 2023 (¥400.4 Mil) but then increased from Dec. 2023 (¥400.4 Mil) to Mar. 2024 (¥471.5 Mil).

Chongqing Lummy Pharmaceutical's annual accounts payable & accrued expense declined from Dec. 2021 (¥466.6 Mil) to Dec. 2022 (¥464.3 Mil) and declined from Dec. 2022 (¥464.3 Mil) to Dec. 2023 (¥400.4 Mil).

Chongqing Lummy Pharmaceutical Accounts Payable & Accrued Expense Historical Data

The historical data trend for Chongqing Lummy Pharmaceutical's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Lummy Pharmaceutical Accounts Payable & Accrued Expense Chart

Chongqing Lummy Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

528.45

575.13

466.63

464.28

400.35

Chongqing Lummy Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															500.89	471.12	420.14	400.35	471.53

Chongqing Lummy Pharmaceutical Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Chongqing Lummy Pharmaceutical (SZSE:300006) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chongqing Lummy Pharmaceutical (SZSE:300006) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Yuma Road, Nan'an District, chongqing, CHN, 401123

Website

http://www.cqlummy.com

Chongqing Lummy Pharmaceutical is a wholly-owned subsidiary of Lai America Pharmaceutical Co., Ltd. and is a professional pharmaceutical sales company in China.

Executives

Yuan Yuan	Supervisors
Qiu Yu	Directors, executives
Leng Xue Feng	Secretary, Director
Zhang Xiao Xue	Supervisors
Wang Ying	Director
Zhou Xue Mei	Supervisors
Zhao Bin	Executives
Tang Xiao Hai	Executives
Fu Rong	Executives
Li Xian Feng	Supervisors
Qiu Wei	Director

Chongqing Lummy Pharmaceutical (SZSE:300006) Headlines

No Headlines